Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9BZB8
UPID:
CPEB1_HUMAN
Alternative names:
-
Alternative UPACC:
Q9BZB8; B7Z6C6; Q86W46; Q8IV41; Q9BZB7; Q9H8V5
Background:
Cytoplasmic polyadenylation element-binding protein 1 (CPEB1) plays a pivotal role in mRNA cytoplasmic polyadenylation and translation initiation, crucial for oocyte maturation, early development, and synaptic functions in neurons. It binds to the cytoplasmic polyadenylation element within the mRNA 3'-UTR, undergoing a significant conformational change upon RNA binding. CPEB1's involvement extends to mRNA transport to dendrites, stress granule assembly, and cell cycle progression, specifically prophase entry.
Therapeutic significance:
Understanding the role of Cytoplasmic polyadenylation element-binding protein 1 could open doors to potential therapeutic strategies.